Thiazide and Thiazide-Like Diuretics for Hypertension
Bendroflumethiazide, hydrochlorothiazide, and chlorthalidone are thiazide-type diuretics—a class of first-line antihypertensive medications that lower blood pressure by promoting sodium and water excretion through the kidneys, reducing blood volume and vascular resistance.
Drug Classification and Mechanism
These three medications belong to the thiazide-type diuretic class, though they differ slightly in chemical structure 1, 2, 3:
- Bendroflumethiazide and hydrochlorothiazide (HCTZ): True thiazides containing a benzothiadiazine ring 4
- Chlorthalidone: Technically a "thiazide-like" diuretic lacking this ring structure but functioning similarly 5
All three work by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney, promoting natriuresis (sodium excretion) and subsequent water loss, which reduces intravascular volume and ultimately lowers blood pressure 6, 7.
Why They're Used for Hypertension Management
Proven Cardiovascular Benefits
Thiazide-type diuretics are recommended as first-line therapy because high-quality randomized controlled trials have demonstrated they prevent cardiovascular disease events including myocardial infarction, stroke, heart failure, and cardiovascular death 2. The evidence base is particularly strong—these medications have been tested in landmark trials showing mortality and morbidity reduction 6, 8.
Guideline-Recommended First-Line Agents
Current guidelines position thiazide-type diuretics alongside three other drug classes (ACE inhibitors, ARBs, and calcium channel blockers) as preferred initial therapy 2, 7:
- For patients >55 years old: Thiazide-type diuretics are recommended when calcium channel blockers are unsuitable or when heart failure risk is present 1
- For Black patients of any age: Thiazide-type diuretics serve as alternatives to calcium channel blockers 1
- For combination therapy: Thiazide-type diuretics combine effectively with ACE inhibitors, ARBs, or calcium channel blockers in Step 2 and Step 3 treatment algorithms 1
Important Distinctions Between Specific Agents
When initiating or changing diuretic therapy, chlorthalidone (12.5-25 mg daily) or indapamide should be preferred over conventional thiazides like bendroflumethiazide or hydrochlorothiazide 1. This recommendation stems from:
- Superior 24-hour blood pressure control: Chlorthalidone provides greater systolic BP reduction (approximately 5 mmHg more) and diastolic BP reduction (approximately 3 mmHg more) compared to HCTZ, with particularly better nocturnal control 9, 10, 11
- Longer half-life: Chlorthalidone's extended duration of action (40-60 hours vs. 6-12 hours for HCTZ) provides more consistent BP lowering 12, 9
- Stronger trial evidence: Most major cardiovascular outcome trials (ALLHAT, SHEP) used chlorthalidone, not HCTZ 6, 13, 12
Critical Caveat on Switching
However, if patients are already stable and well-controlled on bendroflumethiazide or hydrochlorothiazide, continue their current therapy rather than switching 1. A large pragmatic trial found no significant cardiovascular benefit when switching from HCTZ to chlorthalidone in stable patients 2.
Practical Dosing Considerations
Effective doses used in successful morbidity trials 6:
- Hydrochlorothiazide: 25-50 mg once daily
- Chlorthalidone: 12.5-25 mg once daily
- Bendroflumethiazide: 5 mg once daily (in combination products) 4
Higher doses add minimal antihypertensive benefit but increase adverse effects, particularly hypokalemia 6.
Safety Profile and Monitoring
Common Side Effects
- Electrolyte abnormalities: Hypokalemia (more common with chlorthalidone), hyponatremia 6, 13, 10, 14
- Metabolic effects: Hyperuricemia (rarely causing gout at recommended doses), mild glucose elevation, potential new-onset diabetes 6, 8
- Renal effects: Chlorthalidone carries higher risk of acute kidney injury and chronic kidney disease compared to HCTZ 14, 15
Monitoring Requirements
Check serum sodium, potassium, and renal function within 2-4 weeks after initiation or dose escalation 1, 13, 1. This is particularly important with chlorthalidone given its higher risk of electrolyte disturbances 10, 14, 15.
Comparative Safety
Recent large-scale observational studies reveal chlorthalidone causes significantly more hypokalemia (HR 2.72), hyponatremia (HR 1.31), and acute renal failure (HR 1.37) compared to HCTZ 14, 15. Despite superior BP lowering, these safety concerns must be weighed against potential cardiovascular benefits.
Special Populations
Advanced Chronic Kidney Disease
Thiazide-type diuretics, particularly chlorthalidone, remain effective even with eGFR <30 mL/min/1.73 m² 13. Don't automatically discontinue when kidney function declines—one study showed chlorthalidone 25 mg reduced 24-hour ambulatory BP by 10.5 mmHg in patients with mean eGFR of 27 mL/min/1.73 m² 13. However, loop diuretics may be needed for volume control at very low GFR.
Resistant Hypertension
In Step 4 treatment for resistant hypertension, increasing thiazide-like diuretic doses is appropriate when serum potassium >4.5 mmol/L 1. Volume expansion frequently underlies treatment resistance, making adequate diuresis essential 9.
Bottom Line Algorithm
For new diuretic prescriptions in hypertension:
- Choose chlorthalidone 12.5-25 mg daily over HCTZ or bendroflumethiazide for superior BP control 1, 2, 1, 7
- Monitor electrolytes and renal function within 2-4 weeks 1, 13
- Accept higher hypokalemia risk with chlorthalidone; supplement potassium or use potassium-sparing agents if needed 10, 14
For patients already stable on HCTZ or bendroflumethiazide:
In advanced CKD (eGFR <30):